A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Sotatercept (Primary)
- Indications Heart failure; Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms CADENCE
- Sponsors Acceleron Pharma
Most Recent Events
- 20 Mar 2025 Planned End Date changed from 20 Feb 2027 to 12 Sep 2025.
- 20 Mar 2025 Planned primary completion date changed from 31 Oct 2025 to 12 Sep 2025.
- 20 Mar 2025 Status changed from recruiting to active, no longer recruiting.